Victoria Tatiana Kronsten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Victoria Tatiana Kronsten has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Debbie Lindsay Shawcross
Roger Williams Institute of Liver Studies, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, UK
6 shared publications - Thomas Henry Tranah
Roger Williams Institute of Liver Studies, King’s College London Faculty of Life Sciences and Medicine, London, UK
5 shared publications Debbie L Shawcross
Roger Williams Institute of Liver Studies, King’s College London Faculty of Life Sciences & Medicine, London, UK
3 shared publicationsDebbie L. Shawcross
Roger Williams Institute of Liver Studies, Faculty of Life Sciences and Medicine, King's College London, London, UK
3 shared publicationsAlberto Sanchez-Fueyo
Institute of Liver Studies, Department of Inflammation Biology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, United Kingdom
2 shared publicationsChiara Mangini
Department of Medicine, University of Padova, Padova, Italy
2 shared publications
Latest Publications
- 28 May 2026
- Published by BMJ in Frontline Gastroenterology
- Vol. 17 (4) , 357-369
Hepatic encephalopathy: Part 3, outpatient management
Hepatic encephalopathy (HE) represents a common and debilitating complication of cirrhosis, with a heterogeneous range of symptoms, severity, time course and impact on both patients and caregivers alike. HE represents a transitional point in the natural history of chronic liver disease and is associated with a substantial decline in quality of life, alongside increased healthcare resource utilisation and mortality. Treatment goals for HE centre on improvement in quality of life, prevention of episodes of both overt HE and other acute decompensating events associated with cirrhosis and portal hypertension. Multidisciplinary teams, including specialists in hepatology, nutrition, nursing, physiotherapy, social workers and, where appropriate, palliative medicine, help to provide comprehensive and holistic care and are important in securing the best patient outcomes. Part 3 of this review series focuses on the outpatient management of HE in addition to considering distinct clinical presentations and specific challenges posed by HE. We outline approaches to assessing the severity of HE and response to treatment. We discuss patient and carer education and highlight its importance for empowering community management, optimising medical treatment and reducing hospital admissions and resource utilisation. We outline a stepwise algorithm for the treatment of symptomatic HE, including non-absorbable disaccharides, rifaximin-α and L-Ornithine L-Aspartate and discuss when to refer for transplant assessment. Furthermore, we highlight challenges in therapeutic drug development in this field and propose a framework for consideration of trial endpoints in patients with either covert or a history of overt HE, recognising the need for modern trial designs in delivering translational therapeutics.
- 28 May 2026
- Published by BMJ in Frontline Gastroenterology
- Vol. 17 (4) , 357-369
Hepatic encephalopathy: Part 3, outpatient management
Hepatic encephalopathy (HE) represents a common and debilitating complication of cirrhosis, with a heterogeneous range of symptoms, severity, time course and impact on both patients and caregivers alike. HE represents a transitional point in the natural history of chronic liver disease and is associated with a substantial decline in quality of life, alongside increased healthcare resource utilisation and mortality. Treatment goals for HE centre on improvement in quality of life, prevention of episodes of both overt HE and other acute decompensating events associated with cirrhosis and portal hypertension. Multidisciplinary teams, including specialists in hepatology, nutrition, nursing, physiotherapy, social workers and, where appropriate, palliative medicine, help to provide comprehensive and holistic care and are important in securing the best patient outcomes. Part 3 of this review series focuses on the outpatient management of HE in addition to considering distinct clinical presentations and specific challenges posed by HE. We outline approaches to assessing the severity of HE and response to treatment. We discuss patient and carer education and highlight its importance for empowering community management, optimising medical treatment and reducing hospital admissions and resource utilisation. We outline a stepwise algorithm for the treatment of symptomatic HE, including non-absorbable disaccharides, rifaximin-α and L-Ornithine L-Aspartate and discuss when to refer for transplant assessment. Furthermore, we highlight challenges in therapeutic drug development in this field and propose a framework for consideration of trial endpoints in patients with either covert or a history of overt HE, recognising the need for modern trial designs in delivering translational therapeutics.
- 1 October 2025
- Published by BMJ in Frontline Gastroenterology
- Vol. 17 (4) , 345-356
Hepatic encephalopathy: Part 2, inpatient management
The second of this four-part review encompasses the inpatient management of hepatic encephalopathy (HE) in patients with decompensated cirrhosis, acute-on-chronic liver failure (ACLF) and acute liver failure (ALF). The management of overt HE in cirrhosis consists of excluding alternative causes of altered mental state, identifying and correcting precipitants, instigating nutritional support and initiating pharmacological therapy. The presence of HE in combination with other organ failures defines ACLF, and these patients are frequently managed in the intensive care setting. Aside from the treatment of precipitants and organ support in ACLF, there is an emerging role for emergency liver transplantation in highly selected patients. ALF is characterised by the development of severe hepatocellular injury accompanied by coagulopathy and HE, in patients usually without pre-existing chronic liver disease. The often rapid development of hyperammonaemia in ALF may culminate in cerebral oedema and intracranial hypertension, which is specific to this syndrome and, as such, management of HE in ALF differs from that in cirrhosis. A package of neuroprotective care is delivered, including specific monitoring for cerebral oedema, and osmotic therapy is employed for surges in intracranial pressure. Specific ammonia-lowering therapies recommended include continuous renal replacement therapy and therapeutic plasma exchange, with emergency liver transplantation the definitive treatment in the absence of liver regeneration and spontaneous recovery. Independent of underlying aetiology, patients with grade 3–4 HE should be managed in the intensive care unit due to risk of airway compromise and aspiration.
- 1 October 2025
- Published by BMJ in Frontline Gastroenterology
- Vol. 17 (4) , 345-356
Hepatic encephalopathy: Part 2, inpatient management
The second of this four-part review encompasses the inpatient management of hepatic encephalopathy (HE) in patients with decompensated cirrhosis, acute-on-chronic liver failure (ACLF) and acute liver failure (ALF). The management of overt HE in cirrhosis consists of excluding alternative causes of altered mental state, identifying and correcting precipitants, instigating nutritional support and initiating pharmacological therapy. The presence of HE in combination with other organ failures defines ACLF, and these patients are frequently managed in the intensive care setting. Aside from the treatment of precipitants and organ support in ACLF, there is an emerging role for emergency liver transplantation in highly selected patients. ALF is characterised by the development of severe hepatocellular injury accompanied by coagulopathy and HE, in patients usually without pre-existing chronic liver disease. The often rapid development of hyperammonaemia in ALF may culminate in cerebral oedema and intracranial hypertension, which is specific to this syndrome and, as such, management of HE in ALF differs from that in cirrhosis. A package of neuroprotective care is delivered, including specific monitoring for cerebral oedema, and osmotic therapy is employed for surges in intracranial pressure. Specific ammonia-lowering therapies recommended include continuous renal replacement therapy and therapeutic plasma exchange, with emergency liver transplantation the definitive treatment in the absence of liver regeneration and spontaneous recovery. Independent of underlying aetiology, patients with grade 3–4 HE should be managed in the intensive care unit due to risk of airway compromise and aspiration.
- 9 June 2025
- Published by BMJ in Frontline Gastroenterology
- Vol. 17 (4) , 331-344
Hepatic encephalopathy: Part 1, a diagnostic approach
The first of this three-part review provides an overview of the clinical features, differential diagnoses and practical approach to the patient with hepatic encephalopathy (HE). HE is a debilitating condition seen in acute and chronic liver disease and/or portal-systemic shunting. Decades of research support the pathophysiological determination of a synergistic effect of gut-derived inflammation, infection and ammonia in its development. While HE is a distinct clinicopathological entity, patients with liver disease or portal hypertension remain vulnerable to other causes of altered mental state common in the general population. As there is no definitive test for overt HE, diagnosis relies on exclusion of differential diagnoses, considering several treatable conditions. We propose a four-step approach for identifying HE in patients presenting to the emergency department or outpatient clinics: (1) defining the underlying disease, (2) clinical characterisation, (3) identifying precipitants and risk factors and (4) excluding alternative diagnoses. Additionally, we will discuss the use of neuropsychological and neurophysiological testing for the diagnosis of covert HE. The second instalment of this review series will cover the investigation and management of HE in acute and acute-on-chronic liver failure, and the third instalment will cover outpatient management of HE.
- 9 June 2025
- Published by BMJ in Frontline Gastroenterology
- Vol. 17 (4) , 331-344
Hepatic encephalopathy: Part 1, a diagnostic approach
The first of this three-part review provides an overview of the clinical features, differential diagnoses and practical approach to the patient with hepatic encephalopathy (HE). HE is a debilitating condition seen in acute and chronic liver disease and/or portal-systemic shunting. Decades of research support the pathophysiological determination of a synergistic effect of gut-derived inflammation, infection and ammonia in its development. While HE is a distinct clinicopathological entity, patients with liver disease or portal hypertension remain vulnerable to other causes of altered mental state common in the general population. As there is no definitive test for overt HE, diagnosis relies on exclusion of differential diagnoses, considering several treatable conditions. We propose a four-step approach for identifying HE in patients presenting to the emergency department or outpatient clinics: (1) defining the underlying disease, (2) clinical characterisation, (3) identifying precipitants and risk factors and (4) excluding alternative diagnoses. Additionally, we will discuss the use of neuropsychological and neurophysiological testing for the diagnosis of covert HE. The second instalment of this review series will cover the investigation and management of HE in acute and acute-on-chronic liver failure, and the third instalment will cover outpatient management of HE.
- 27 February 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (6) , 699-700
A holistic approach is needed for the treatment of alcohol use disorder
An abstract is unavailable. This article is available as a PDF only.
- 27 February 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (6) , 699-700
A holistic approach is needed for the treatment of alcohol use disorder
An abstract is unavailable. This article is available as a PDF only.
- 24 January 2025
- Published by Elsevier in Gastroenterology
- Vol. 168 (6) , 1076-1084.e1
Hepatic Encephalopathy: When Lactulose and Rifaximin Are Not Working
- 24 January 2025
- Published by Elsevier in Gastroenterology
- Vol. 168 (6) , 1076-1084.e1
Hepatic Encephalopathy: When Lactulose and Rifaximin Are Not Working
- 10 December 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (3) , 406-410
Adolescent sobriety under siege – an urgent call to protect children from alcohol harms
- 10 December 2024
- Published by Elsevier in Journal of Hepatology
- Vol. 82 (3) , 406-410
Adolescent sobriety under siege – an urgent call to protect children from alcohol harms
- Open Access
- 27 August 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (1) , 65-74
Clinical Implications of Inflammation in Patients With Cirrhosis
Cirrhosis-associated immune dysfunction refers to the concurrent systemic inflammation and immunoparesis evident across the disease spectrum of chronic liver disease, ranging from the low-grade inflammatory plasma milieu that accompanies compensated disease to the intense high-grade inflammatory state with coexistent severe immune paralysis that defines acute decompensation and acute-on-chronic liver failure. Systemic inflammation plays a crucial role in the disease course of cirrhosis and is a key driver for acute decompensation and the progression from compensated to decompensated cirrhosis. Severe systemic inflammation is fundamental to the development of organ dysfunction and failure and, in its most extreme form, acute-on-chronic liver failure. Systemic inflammation propagates the development of hepatic encephalopathy and hepatorenal syndrome-acute kidney injury. It may also be involved in the pathogenesis of further complications such as hepatocellular carcinoma and mental illness. Those patients with the most profound systemic inflammation have the worst prognosis. Systemic inflammation exerts its negative clinical effects through a number of mechanisms including nitric oxide-mediated increased splanchnic vasodilation, immunopathology, and metabolic reallocation.
- 27 August 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (1) , 65-74
Open AccessClinical Implications of Inflammation in Patients With Cirrhosis
Cirrhosis-associated immune dysfunction refers to the concurrent systemic inflammation and immunoparesis evident across the disease spectrum of chronic liver disease, ranging from the low-grade inflammatory plasma milieu that accompanies compensated disease to the intense high-grade inflammatory state with coexistent severe immune paralysis that defines acute decompensation and acute-on-chronic liver failure. Systemic inflammation plays a crucial role in the disease course of cirrhosis and is a key driver for acute decompensation and the progression from compensated to decompensated cirrhosis. Severe systemic inflammation is fundamental to the development of organ dysfunction and failure and, in its most extreme form, acute-on-chronic liver failure. Systemic inflammation propagates the development of hepatic encephalopathy and hepatorenal syndrome-acute kidney injury. It may also be involved in the pathogenesis of further complications such as hepatocellular carcinoma and mental illness. Those patients with the most profound systemic inflammation have the worst prognosis. Systemic inflammation exerts its negative clinical effects through a number of mechanisms including nitric oxide-mediated increased splanchnic vasodilation, immunopathology, and metabolic reallocation.
- 5 July 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (4) , 519-520
Editorial: Sounding the alarm—The rising global burden of adolescent and young adult alcohol‐related liver disease
LINKED CONTENT: This article is linked to Danpanichkul et al papers. To view these articles, visit https://doi.org/10.1111/apt.18101 and https://doi.org/10.1111/apt.18157
- 5 July 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 60 (4) , 519-520
Editorial: Sounding the alarm—The rising global burden of adolescent and young adult alcohol‐related liver disease
LINKED CONTENT: This article is linked to Danpanichkul et al papers. To view these articles, visit https://doi.org/10.1111/apt.18101 and https://doi.org/10.1111/apt.18157
- Open Access
- 1 July 2022
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 9 (7) , e00824
Tonsillar Extraintestinal Enteropathy-Associated T-Cell Lymphoma in a Patient With Celiac Disease
Enteropathy-associated T-cell lymphoma (EATL) is a rare but serious complication of celiac disease. Diagnosis is challenging. Patients can present with weight loss, abdominal pain, and diarrhea or acutely with bowel perforation or obstruction. Patients often present with advanced disease. Malnutrition further limits treatment options. Early diagnosis is important to start aggressive treatment strategies. However, even with prompt diagnosis, prognosis remains poor with a high mortality rate. We report the first documented case of sole tonsillar involvement, a rare extraintestinal and extranodal site of disease, leading to EATL diagnosis. We also highlight some of the challenges in diagnosing EATL.
- 1 July 2022
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 9 (7) , e00824
Open AccessTonsillar Extraintestinal Enteropathy-Associated T-Cell Lymphoma in a Patient With Celiac Disease
Enteropathy-associated T-cell lymphoma (EATL) is a rare but serious complication of celiac disease. Diagnosis is challenging. Patients can present with weight loss, abdominal pain, and diarrhea or acutely with bowel perforation or obstruction. Patients often present with advanced disease. Malnutrition further limits treatment options. Early diagnosis is important to start aggressive treatment strategies. However, even with prompt diagnosis, prognosis remains poor with a high mortality rate. We report the first documented case of sole tonsillar involvement, a rare extraintestinal and extranodal site of disease, leading to EATL diagnosis. We also highlight some of the challenges in diagnosing EATL.
P98 Formal regional referral networks optimize patient selection for liver transplantation
Introduction Unlike other conditions with high mortality (eg hepatocellular carcinoma (HCC)) chronic liver disease (CLD) patients (PTs) in the United Kingdom do not have standardised referral pathways. To improve access to liver transplantation (LT), King’s College Hospital (KCH) developed a network of satellite LT centres (SLTCs). We aimed to evaluate the impact of SLTCs in LT candidacy evaluation in CLD PTs and those within the established HCC pathway. Methods All PTs discussed at the KCH LT meeting between 10/2014-10/2019 were included. All second opinions from other centres and PTs without CLD or HCC were excluded. Geographic, referral (KCH, SLTC or conventional referrer (CR)), clinical, demographic and laboratory data were retrospectively recorded. HCC PTs had tumor related variables recorded. CLD and HCC PTs were analyzed separately. Univariate (UVA) and multivariate analyses (MVA) were utilized to assess the impact of SLTCs. Results 1102 assessments from CLD PTs (CR=512 SLTC=299 KCH=291) and 240 assessments from HCC PTs (CR=110 SLTC=72 KCH=58) were included. HCC PTs were not significantly more likely to be; referred from CRs/SLTCs/KCH, listed or have a contraindication to LT than CLD PTs. 725 CLD PTs were listed and 216 had contraindications to LT. Variables significantly associated with listing included; younger age, autoimmune liver diseases (AILD), biliary atresia (BA), previous LT, higher CLD prognostic scores, shorter referral to decision time and referral from SLTCs. Variables significantly negatively associated with listing included; non-alcoholic fatty liver disease (NAFLD), alcohol related liver disease (ARLD), hepatitis C and referral from CRs. MVA was utilized to demonstrate that referrals from SLTCs remained independently associated with listing (adjusted odds ratio (aOR) 2.92 (95% confidence interval (CI) 2.07-4.17)). Variables associated with contraindication to LT included; older age, ARLD, NAFLD, higher CLD prognostic scores and referral from CRs. Variables negatively associated with contraindication to LT included; AILD, BA, previous LT or referral from SLTC. MVA was utilized to demonstrate that referrals from SLTC remained independently negatively associated with contraindications (aOR 0.33 (95%CI 0.21-0.50)). 168 HCC patients were listed and 55 had contraindications to LT. No variables were significantly associated with listing including referrals from SLTC on UVA or MVA. Older HCC PTs were significantly more likely to have a contraindication to LT but referrals from SLTC did not influence likelihood on UVA or MVA. Conclusions Formal referral pathways through SLTCs improve PT selection and access to LT for PTs with CLD but do not impact on the well-established HCC pathway.
P98 Formal regional referral networks optimize patient selection for liver transplantation
Introduction Unlike other conditions with high mortality (eg hepatocellular carcinoma (HCC)) chronic liver disease (CLD) patients (PTs) in the United Kingdom do not have standardised referral pathways. To improve access to liver transplantation (LT), King’s College Hospital (KCH) developed a network of satellite LT centres (SLTCs). We aimed to evaluate the impact of SLTCs in LT candidacy evaluation in CLD PTs and those within the established HCC pathway. Methods All PTs discussed at the KCH LT meeting between 10/2014-10/2019 were included. All second opinions from other centres and PTs without CLD or HCC were excluded. Geographic, referral (KCH, SLTC or conventional referrer (CR)), clinical, demographic and laboratory data were retrospectively recorded. HCC PTs had tumor related variables recorded. CLD and HCC PTs were analyzed separately. Univariate (UVA) and multivariate analyses (MVA) were utilized to assess the impact of SLTCs. Results 1102 assessments from CLD PTs (CR=512 SLTC=299 KCH=291) and 240 assessments from HCC PTs (CR=110 SLTC=72 KCH=58) were included. HCC PTs were not significantly more likely to be; referred from CRs/SLTCs/KCH, listed or have a contraindication to LT than CLD PTs. 725 CLD PTs were listed and 216 had contraindications to LT. Variables significantly associated with listing included; younger age, autoimmune liver diseases (AILD), biliary atresia (BA), previous LT, higher CLD prognostic scores, shorter referral to decision time and referral from SLTCs. Variables significantly negatively associated with listing included; non-alcoholic fatty liver disease (NAFLD), alcohol related liver disease (ARLD), hepatitis C and referral from CRs. MVA was utilized to demonstrate that referrals from SLTCs remained independently associated with listing (adjusted odds ratio (aOR) 2.92 (95% confidence interval (CI) 2.07-4.17)). Variables associated with contraindication to LT included; older age, ARLD, NAFLD, higher CLD prognostic scores and referral from CRs. Variables negatively associated with contraindication to LT included; AILD, BA, previous LT or referral from SLTC. MVA was utilized to demonstrate that referrals from SLTC remained independently negatively associated with contraindications (aOR 0.33 (95%CI 0.21-0.50)). 168 HCC patients were listed and 55 had contraindications to LT. No variables were significantly associated with listing including referrals from SLTC on UVA or MVA. Older HCC PTs were significantly more likely to have a contraindication to LT but referrals from SLTC did not influence likelihood on UVA or MVA. Conclusions Formal referral pathways through SLTCs improve PT selection and access to LT for PTs with CLD but do not impact on the well-established HCC pathway.